Annual CFO
-$145.37 M
-$52.85 M-57.12%
December 31, 2023
Summary
- As of February 12, 2025, AKRO annual cash flow from operations is -$145.37 million, with the most recent change of -$52.85 million (-57.12%) on December 31, 2023.
- During the last 3 years, AKRO annual CFO has fallen by -$74.56 million (-105.31%).
- AKRO annual CFO is now -3043.07% below its all-time high of -$4.63 million, reached on December 31, 2018.
Performance
AKRO Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$70.42 M
-$12.97 M-22.58%
September 30, 2024
Summary
- As of February 12, 2025, AKRO quarterly cash flow from operations is -$70.42 million, with the most recent change of -$12.97 million (-22.58%) on September 30, 2024.
- Over the past year, AKRO quarterly CFO has dropped by -$20.70 million (-41.64%).
- AKRO quarterly CFO is now -27957.37% below its all-time high of -$251.00 thousand, reached on June 30, 2018.
Performance
AKRO Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$211.64 M
-$20.70 M-10.84%
September 30, 2024
Summary
- As of February 12, 2025, AKRO TTM cash flow from operations is -$211.64 million, with the most recent change of -$20.70 million (-10.84%) on September 30, 2024.
- Over the past year, AKRO TTM CFO has dropped by -$89.40 million (-73.13%).
- AKRO TTM CFO is now -62516.57% below its all-time high of -$338.00 thousand, reached on March 31, 2018.
Performance
AKRO TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
AKRO Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -57.1% | -41.6% | -73.1% |
| 3 y3 years | -105.3% | -382.2% | -177.1% |
| 5 y5 years | -3043.1% | -433.0% | -494.1% |
AKRO Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -82.4% | at low | -261.0% | at low | -165.6% | at low |
| 5 y | 5-year | -308.0% | at low | -522.3% | at low | -494.1% | at low |
| alltime | all time | -3043.1% | at low | <-9999.0% | at low | <-9999.0% | at low |
Akero Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$70.42 M(+22.6%) | -$211.64 M(+10.8%) |
| Jun 2024 | - | -$57.45 M(+63.5%) | -$190.94 M(+22.5%) |
| Mar 2024 | - | -$35.14 M(-27.7%) | -$155.88 M(+7.2%) |
| Dec 2023 | -$145.37 M(+57.1%) | -$48.63 M(-2.2%) | -$145.37 M(+18.9%) |
| Sep 2023 | - | -$49.72 M(+122.1%) | -$122.25 M(+25.8%) |
| Jun 2023 | - | -$22.39 M(-9.1%) | -$97.15 M(+3.1%) |
| Mar 2023 | - | -$24.63 M(-3.4%) | -$94.27 M(+1.9%) |
| Dec 2022 | -$92.52 M(+16.1%) | -$25.51 M(+3.6%) | -$92.52 M(-1.3%) |
| Sep 2022 | - | -$24.62 M(+26.2%) | -$93.70 M(+12.0%) |
| Jun 2022 | - | -$19.51 M(-14.7%) | -$83.69 M(-0.6%) |
| Mar 2022 | - | -$22.88 M(-14.3%) | -$84.21 M(+5.7%) |
| Dec 2021 | -$79.68 M | -$26.70 M(+82.8%) | -$79.68 M(+4.3%) |
| Sep 2021 | - | -$14.61 M(-27.1%) | -$76.38 M(+1.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2021 | - | -$20.03 M(+9.2%) | -$75.28 M(-3.3%) |
| Mar 2021 | - | -$18.35 M(-21.6%) | -$77.83 M(+9.9%) |
| Dec 2020 | -$70.80 M(+98.7%) | -$23.39 M(+73.2%) | -$70.80 M(+19.9%) |
| Sep 2020 | - | -$13.51 M(-40.2%) | -$59.06 M(+0.5%) |
| Jun 2020 | - | -$22.58 M(+99.6%) | -$58.76 M(+41.6%) |
| Mar 2020 | - | -$11.32 M(-2.9%) | -$41.50 M(+16.5%) |
| Dec 2019 | -$35.63 M(+670.3%) | -$11.65 M(-11.8%) | -$35.63 M(+36.7%) |
| Sep 2019 | - | -$13.21 M(+148.3%) | -$26.05 M(+76.0%) |
| Jun 2019 | - | -$5.32 M(-2.2%) | -$14.80 M(+52.1%) |
| Mar 2019 | - | -$5.44 M(+162.4%) | -$9.73 M(+110.4%) |
| Dec 2018 | -$4.63 M | -$2.08 M(+5.8%) | -$4.63 M(+81.4%) |
| Sep 2018 | - | -$1.96 M(+681.3%) | -$2.55 M(+332.9%) |
| Jun 2018 | - | -$251.00 K(-25.7%) | -$589.00 K(+74.3%) |
| Mar 2018 | - | -$338.00 K | -$338.00 K |
FAQ
- What is Akero Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Akero Therapeutics?
- What is Akero Therapeutics annual CFO year-on-year change?
- What is Akero Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Akero Therapeutics?
- What is Akero Therapeutics quarterly CFO year-on-year change?
- What is Akero Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Akero Therapeutics?
- What is Akero Therapeutics TTM CFO year-on-year change?
What is Akero Therapeutics annual cash flow from operations?
The current annual CFO of AKRO is -$145.37 M
What is the all time high annual CFO for Akero Therapeutics?
Akero Therapeutics all-time high annual cash flow from operations is -$4.63 M
What is Akero Therapeutics annual CFO year-on-year change?
Over the past year, AKRO annual cash flow from operations has changed by -$52.85 M (-57.12%)
What is Akero Therapeutics quarterly cash flow from operations?
The current quarterly CFO of AKRO is -$70.42 M
What is the all time high quarterly CFO for Akero Therapeutics?
Akero Therapeutics all-time high quarterly cash flow from operations is -$251.00 K
What is Akero Therapeutics quarterly CFO year-on-year change?
Over the past year, AKRO quarterly cash flow from operations has changed by -$20.70 M (-41.64%)
What is Akero Therapeutics TTM cash flow from operations?
The current TTM CFO of AKRO is -$211.64 M
What is the all time high TTM CFO for Akero Therapeutics?
Akero Therapeutics all-time high TTM cash flow from operations is -$338.00 K
What is Akero Therapeutics TTM CFO year-on-year change?
Over the past year, AKRO TTM cash flow from operations has changed by -$89.40 M (-73.13%)